Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI109701

Metabolic Consequences of Oral Administration of 24,25-Dihydroxycholecalciferol to Uremic Dogs

Janet M. Canterbury, George Gavellas, Jacques J. Bourgoignie, and Eric Reiss

Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101

Laboratory of the Howard Hughes Medical Institute, University of Miami School of Medicine, Miami, Florida 33101

Find articles by Canterbury, J. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101

Laboratory of the Howard Hughes Medical Institute, University of Miami School of Medicine, Miami, Florida 33101

Find articles by Gavellas, G. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101

Laboratory of the Howard Hughes Medical Institute, University of Miami School of Medicine, Miami, Florida 33101

Find articles by Bourgoignie, J. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101

Laboratory of the Howard Hughes Medical Institute, University of Miami School of Medicine, Miami, Florida 33101

Find articles by Reiss, E. in: JCI | PubMed | Google Scholar

Published March 1, 1980 - More info

Published in Volume 65, Issue 3 on March 1, 1980
J Clin Invest. 1980;65(3):571–576. https://doi.org/10.1172/JCI109701.
© 1980 The American Society for Clinical Investigation
Published March 1, 1980 - Version history
View PDF
Abstract

24,25-dihydroxycholecalciferol [24,25-(OH)2D3], once considered a relatively inert metabolite of vitamin D3, has been recently recognized as a metabolically active product in some species. In previous studies, we have shown that infusion of 24,25(OH)2D3 into the thyroid artery of normal dogs results in prompt and complete suppression of parathyroid hormone (PTH) secretion. In this study, we have examined the metabolic consequences of oral administration of this metabolite in dogs with experimentally induced renal hyperparathyroidism. Dogs with comparable degrees of renal insufficiency (glomerular filtration rate, 10-15 ml/min) were treated for 3 wk with daily doses of either 2 μg of 24,25(OH)2D3 or 50% ethanol, the vehicle in which the metabolite was suspended. After a 6-wk recovery period, treatments were reversed: dogs who had previously served as controls received the metabolite while dogs previously treated with metabolite received the vehicle. Administration of 24,25(OH)2D3 resulted in a 40-60% decrease of immunoreactive PTH. This was associated with a small (0.1-0.2 mg/dl) but unequivocal decrease of serum ionized calcium. Calcium balance, which was slightly negative under control conditions, became slightly but definitively positive on treatment with 24,25(OH)2D3. All other parameters measured, including total serum calcium, magnesium, phosphorus, creatinine, electrolytes, phosphorus excretion, and phosphorus balance, remained unchanged. The data support the hypothesis that 24,25(OH)2D3 not only decreases PTH secretion but also functions as an anabolic hormone in bone under the conditions of this experiment.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 571
page 571
icon of scanned page 572
page 572
icon of scanned page 573
page 573
icon of scanned page 574
page 574
icon of scanned page 575
page 575
icon of scanned page 576
page 576
Version history
  • Version 1 (March 1, 1980): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts